Grunenthal announced the termination of the license agreement with Actavis for the development and commercialization of Cebranopadol, a novel analgesic for the treatment of chronic pain.
Forest Laboratories Ireland and Grünenthal had entered into a license agreement on Cebranopadol in December 2010.
This agreement included the co-development and commercialization of Cebranopadol (GRT6005), with exclusive rights for Actavis in the United States and Canada, while Grünenthal held the rights in Europe and the rest of the world.
Grünenthal continues the development program as planned.
The termination of the license agreement does not have any impact on the enrollment status of patients who are currently participating in the ongoing clinical trials in Europe and the US.
For further deal information visit Current Agreements (subscription required)
Report: Top 50 Big Biotech Partnering and M&A Deal Trends